Covaxx inks supply deals worth $2.8B in lead-up to coronavirus vaccine midstage trials

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 25, 2020 at 11:22 AM.

  1. #1 cafead, Nov 25, 2020 at 11:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,057
    Likes Received:
    3
    via While some of the leading players in the race for a COVID-19 vaccine are racing toward the finish line, a range of smaller challengers is still hoping to carve out a market niche in the coming months. One of those, New York's Covaxx, is rolling out its first swath of supply deals—and touting its shot's logistics advantage.

    Covaxx has inked a trio of deals with three South American nations to provide up to 140 million doses of its COVID-19 vaccine at a price tag of $2.8 billion as the drugmaker prepares to enter phase 2/3 testing later this year.

    article source
     
    Quote

Reply to Thread